HUTH ANDREAS
No ORCID on file
· 42 papers in corpus
· active 2002-2009
Frequent coauthors
- KRUEGER MARTIN 42
- MENRAD ANDREAS 42
- HABEREY MARTIN 40
- THIERAUCH KARL-HEINZ 32
- ERNST Alexander 22
- HESS-STUMPP HOLGER 20
- ZORN LUDWIG 20
- INCE STUART 18
- THIERAUCH KARL HEINZ 6
- INCE STUAT 4
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2008
Substituted cyanoanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in …
2008
Substituted cyanoanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in …
2008
Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in…
2008
Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2006
Substituted cyanoanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in …
2006
Substituted cyanoanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in …
2006
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2006
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2005
Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in…
2005
Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …